Original Article
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer

https://doi.org/10.1038/jid.2008.449Get rights and content
Under an Elsevier user license
open archive

Matriptase (membrane-type serine proteinase) was reported to play a role in nonmelanoma skin cancer progression. Moreover, it was shown to stimulate proteinase-activated receptor-2 (PAR2) in vitro. Hepatocyte growth factor activator inhibitor-1 (HAI-1), the matriptase inhibitor, is an important regulator of enzyme activity. Therefore, the aim of this study was to elucidate the putative role of matriptase, HAI-1, and PAR2 in normal human skin, as well as in basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs). In normal human epidermis, PAR2 colocalized with matriptase and HAI-1. Immunoreactivity of all proteins was found to be diminished in BCCs. Likewise, PAR2 immunoreactivity was significantly decreased, whereas matriptase immunoreactivity was enhanced with SCC progression. We could also show that matriptase was complexed to HAI-1 in normal human skin, whereas in SCCs, the enzyme was present in an unassociated form. Both a specific peptide agonist for PAR2 and the proteinase domain of matriptase were able to induce intracellular calcium mobilization and inhibition of proliferation in cultured HaCaT keratinocytes. In conclusion, our results suggest that PAR2 is a substrate for matriptase in human skin in vivo. Deregulation of these proteins delineates SCC progression.

Cited by (0)

Chen-Yong Lin holds a patent on monoclonal anti-matriptase and anti-HAI-1 antibodies used in this study.

This work was carried out at the University of Münster, Münster, Germany.

7

These authors contributed equally to this work.